Transcriptomics

Dataset Information

0

ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH


ABSTRACT: Recent findings reveal the importance of tryptophan-initiated de novo nicotinamide adenine dinucleotide (NAD+) synthesis in the liver, a process previously considered secondary to biosynthesis from nicotinamide. Here we show that inhibiting α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) promotes de novo NAD+ synthesis and reduces DNA damage ex vivo, in vivo and in human liver organoid (HLO) models. In mouse models of MASLD/MASH, de novo NAD+ biosynthesis is suppressed, and transcriptomic DNA damage signatures correlate with disease severity; In humans, Mendelian randomization-based genetic analysis suggests a notable impact of genomic stress on liver disease susceptibility. Therapeutic inhibiting ACMSD in mice elevates liver NAD+ and reverses MASLD/MASH, mitigating fibrosis, inflammation and DNA damage. Similar outcomes are recapitulated in HLO models of steatohepatitis and DNA damage. Our findings highlight the benefits of ACMSD inhibition for boosting hepatic NAD+ and genomic protection, indicating its therapeutic promise in liver diseases marked by NAD+ and genomic stress.

ORGANISM(S): Mus musculus

PROVIDER: GSE253217 | GEO | 2024/09/22

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-09-23 | GSE253380 | GEO
2010-05-14 | E-GEOD-18909 | biostudies-arrayexpress
2024-10-01 | GSE273523 | GEO
2024-09-16 | GSE271269 | GEO
2024-09-20 | GSE277617 | GEO
2010-02-24 | GSE18909 | GEO
2024-09-22 | GSE275576 | GEO
2024-09-22 | GSE275575 | GEO
2024-06-17 | GSE246221 | GEO
2021-12-31 | MODEL2112310002 | BioModels